Is Brukinsa (Zanubrutinib) a Safer Bruton’s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis

<b>Background/Objectives:</b> Zanubrutinib (Brukinsa) is a next-generation Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, a comprehensive quantitative assessment of its sa...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Helal F. Hetta, Ayman Salama, Turki A. Aljuaid, Yazan T. Mojmami, Riyadh S. Alotibi, Ahmed M. Alqabaly, Nawaf A. Aldosari, Sami A. Alshahri, Walid I. A. Asiri, Raed S. Alamri, Fayez A. Alanazi, Malek S. A. Alenazi, Mohammed H. Albuhayri, Yasmin N. Ramadan, Reem Sayad
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2026-03-01
Reeks:	Pharmaceuticals
Onderwerpen:	zanubrutinib BGB-3111 Bruton’s tyrosine kinase inhibitor chronic lymphocytic leukemia Brukinsa small lymphocytic lymphoma
Online toegang:	https://www.mdpi.com/1424-8247/19/3/467
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!